HR Healthcare Realty Trust (HR) Insider Trading, Ownership & Congress Trades
Real Estate · Real estate investment trusts · CIK 0001360604
Form 144 · 1
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
What the filings say about HR
Insiders, 180 days
-$926.2K net sold
2 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$401.5K
1 notice
Healthcare Realty Trust insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Healthcare Realty Trust Inc insiders sold a net $926.2K of stock across 29 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Dec 17, 2024.
- The trade is 7.6% of the 276,338 shares held after it.
- No other insider sold within 30 days.
Insider activity: EVP and COO Hull Robert E sold about $401.3K of HR on Sep 8, 2026.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 23.4% of the 109,954 shares held after it.
- No other insider sold within 30 days.
Insider activity: SVP & Chief Accounting Officer Callaway Amanda L sold about $524.9K of HR on Jun 23, 2026, the largest insider sale at the company on our record.Context
- 8 earlier Form 4 trades (code P or S) here by this insider (8 buys), the last on Aug 13, 2025.
- +2.6% median (+4.9% mean) 90-day return after 6 previous buys.
- The trade is 11.7% of the 85,520 shares held after it.
- 1 other insider bought within 30 days.
Insider activity: Director Bohjalian Thomas N bought about $180.9K of HR on Mar 6, 2026, the largest insider purchase at the company since 2024; 1 other insider bought within 30 days.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 10 shares held after it.
- 1 other insider bought within 30 days.
Insider activity: EVP, Chief Financial Officer Gabbay Daniel bought about $187 of HR on Mar 4, 2026; 1 other insider bought within 30 days.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Dec 15, 2023.
- The trade is 13.2% of the 113,419 shares held after it.
- No other insider sold within 30 days.
Insider activity: EVP, Chief Admin. Officer Wilson Julie F. sold about $270.0K of HR on Sep 5, 2025, the largest insider sale at the company since 2023.29 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$926.2K over 180 days
-$401.3K over 90 days
below 75% of Real Estate
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
+47.3% year over year
more than 92% of Real Estate
Margin
-872.1% net margin
the lowest in Real Estate
Buybacks
$2.8M repurchased, FY to 2026-06-30
below 70% of Real Estate
Short interest
5.5% of the float short (float per yahoo 2026-10-26) · 3.9 days to cover · settled 2026-09-30
more than 63% of Real Estate
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch HR
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+1.7%12M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns HR: institutional holders (13F)
13F holdings, latest reported quarter
SEC 13F
No reported 13F holders
No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.
Congress trades in HR
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
HR planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Robert E. Hull
Filed 2026-09-08
$401.5K
Amanda L Callaway
Filed 2026-06-22
$519.5K
Executive pay vs shareholder return · Meredith Moore
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$9.5M
$19.3M
$2.1M
-33%
+21%
2023
$6.3M
$4.7M
$2.4M
-37%
-5%
2022
$8.6M
$162.4K
$3.6M
-34%
-17%
2021
$3.2M
$6.5M
$1.6M
+2%
+4%
2020
$2.8M
$1.3M
$1.5M
-8%
-10%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $926.2K sold by insiders over 180 days, $401.5K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
HR financials
Revenue growth
+47.3%
XBRL, annual
Net margin
-872.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.1B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM HR
| FY Dec 2025 | $1.2B |
| FY Dec 2024 | $1.3B |
| FY Dec 2023 | $1.3B |
| FY Dec 2022 | n/a |
| FY Dec 2021 | $767.1M |
| Jun 2026 | $281.8M |
| Mar 2026 | $279.0M |
| Dec 2025 | $286.3M |
| Sep 2025 | $297.8M |
| Jun 2025 | $297.5M |
| Mar 2025 | $299.0M |
| Dec 2024 | $309.8M |
| Sep 2024 | $315.4M |
At each fiscal year end
Single quarter
Net margin, TTM
-7.9%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM HR
| FY Dec 2025 | -21.1% |
| FY Dec 2024 | -52.3% |
| FY Dec 2023 | -21.0% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -15.4% |
| Mar 2026 | -0.0% |
| Dec 2025 | +3.8% |
| Sep 2025 | -19.4% |
| Jun 2025 | -53.1% |
| Mar 2025 | -15.0% |
| Dec 2024 | -37.5% |
| Sep 2024 | -29.5% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$134.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM HR
| FY Dec 2025 | $126.9M |
| FY Dec 2024 | $252.6M |
| FY Dec 2023 | n/a |
| FY Dec 2022 | $109.2M |
| FY Dec 2021 | $135.5M |
| Jun 2026 | $72.4M |
| Mar 2026 | -$8.3M |
| Dec 2025 | $45.8M |
| Sep 2025 | $24.9M |
| Jun 2025 | $77.6M |
| Mar 2025 | -$21.3M |
| Dec 2024 | $75.8M |
| Sep 2024 | $50.3M |
At each fiscal year end
Single quarter
Debt to equity
0.99x
long-term debt only, 2026-06-30; equity 2026-06-30
Debt to equity HR
| FY Dec 2025 | 0.85x |
| FY Dec 2024 | 0.89x |
| FY Dec 2023 | 0.73x |
| FY Dec 2022 | 0.71x |
| FY Dec 2021 | 0.82x |
| Jun 2026 | 0.99x |
| Mar 2026 | 0.92x |
| Dec 2025 | 0.85x |
| Sep 2025 | 0.96x |
| Jun 2025 | 0.97x |
| Mar 2025 | 0.93x |
| Dec 2024 | 0.89x |
| Sep 2024 | 0.90x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.11x
TTM operating cash flow over long-term debt only, 2026-06-30
Cash flow to debt HR
| FY Dec 2025 | 0.12x |
| FY Dec 2024 | 0.11x |
| FY Dec 2023 | 0.10x |
| FY Dec 2022 | 0.05x |
| FY Dec 2021 | 0.13x |
| Jun 2026 | 0.11x |
| Mar 2026 | 0.11x |
| Dec 2025 | 0.12x |
| Sep 2025 | 0.10x |
| Jun 2025 | 0.10x |
| Mar 2025 | 0.10x |
| Dec 2024 | 0.11x |
| Sep 2024 | 0.10x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-2.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity HR
| FY Dec 2025 | -5.1% |
| FY Dec 2024 | -11.0% |
| FY Dec 2023 | -3.9% |
| FY Dec 2022 | +0.8% |
| FY Dec 2021 | n/a |
| Jun 2026 | -2.0% |
| Mar 2026 | -4.3% |
| Dec 2025 | -5.1% |
| Sep 2025 | -7.4% |
| Jun 2025 | -7.7% |
| Mar 2025 | -6.9% |
| Dec 2024 | -11.0% |
| Sep 2024 | -9.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-0.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets HR
| FY Dec 2025 | -2.5% |
| FY Dec 2024 | -5.7% |
| FY Dec 2023 | -2.1% |
| FY Dec 2022 | +0.4% |
| FY Dec 2021 | n/a |
| Jun 2026 | -0.9% |
| Mar 2026 | -2.1% |
| Dec 2025 | -2.5% |
| Sep 2025 | -3.6% |
| Jun 2025 | -3.7% |
| Mar 2025 | -3.5% |
| Dec 2024 | -5.7% |
| Sep 2024 | -4.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital HR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
assets or current liabilities not filed
Return on capital employed HR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing HR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 96.35x |
| FY Dec 2021 | 83.26x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$10.3B
market value at close 2026-10-23 on 2026-07-27 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
Enterprise value HR
| FY Dec 2025 | $9.8B |
| FY Dec 2024 | $10.6B |
| FY Dec 2023 | $11.5B |
| FY Dec 2022 | $12.6B |
| FY Dec 2021 | $8.8B |
| Jun 2026 | $11.1B |
| Mar 2026 | $10.0B |
| Dec 2025 | $9.8B |
| Sep 2025 | $10.8B |
| Jun 2025 | $10.2B |
| Mar 2025 | $10.6B |
| Dec 2024 | $10.6B |
| Sep 2024 | $11.5B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+2.2%
TTM free cash flow over market value at close 2026-10-23
FCF yield HR
| FY Dec 2025 | +2.1% |
| FY Dec 2024 | +4.2% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | +1.5% |
| FY Dec 2021 | +1.9% |
| Jun 2026 | +1.9% |
| Mar 2026 | +2.4% |
| Dec 2025 | +2.1% |
| Sep 2025 | +2.5% |
| Jun 2025 | +3.3% |
| Mar 2025 | +3.5% |
| Dec 2024 | +4.2% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing HR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $1.2B | $1.3B | $1.3B | $932.6M |
| Net income | -$249.5M | -$663.9M | -$282.1M | $40.7M |
| EPS (diluted) | -0.71 | -1.81 | -0.74 | 0.15 |
| Operating cash flow | $457.1M | $501.6M | $499.8M | $272.7M |
| Cash | $26.2M | $68.9M | $25.7M | $61.0M |
| Long-term debt | $3.9B | $4.7B | $5.0B | $5.4B |
| Buybacks | $4.0M | $8.9M | $2.3M | $3.2M |
| Dividends paid | $386.9M | $457.9M | $472.2M | $283.7M |
SEC XBRL, fiscal years, as known on 2026-10-27
HR Stock Sonar score 5/7 axes
Find similar shapesCompareHR ranks highest on growth (93rd percentile) and risk and compliance (68th), and lowest on insider conviction (12th), among Real Estate peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
HR filings, in plain words
Are Healthcare Realty Trust insiders buying or selling HR?
In the 180 days to 2026-10-27, Healthcare Realty Trust insiders were net sellers, a net $926.2K across purchases and sales reported on Form 4, by 2 sellers.
Are there planned insider sales of HR?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-27, covering $401.5K of stock; the latest, by Robert E. Hull, was filed 2026-09-08.
Read the full summary
In the 180 days to 2026-10-27, Healthcare Realty Trust insiders were net sellers of HR, a net $926.2K across purchases and sales reported on Form 4 by 2 sellers. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-27, covering $401.5K of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
